AN2 Therapeutics Inc
Ownership
Ownership Structure
Who owns AN2 Therapeutics Inc (ANTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 56.7% of the shares are freely tradable; institutional investors hold 70.5%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vivo Capital, LLC | 8.36 | 3,153,640 | +0.0 | 06/30/2026 |
| COMMODORE CAPITAL LP | 6.18 | 2,333,713 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 6.14 | 2,318,692 | +4.3 | 06/30/2026 |
| Spruce Street Capital LP | 4.40 | 1,661,073 | +0.0 | 06/30/2026 |
| Almitas Capital LLC | 3.92 | 1,479,129 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.68 | 1,011,078 | +0.0 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 2.65 | 1,000,000 | +0.0 | 06/30/2026 |
| Woodline Partners LP | 2.63 | 993,671 | +580.7 | 03/31/2026 |
| Citadel Advisors Llc | 2.52 | 951,997 | +513.2 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.26 | 853,017 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Readnour Robin Shane | Director | 624,765 | 3,061,349 $ | Sep 9, 2026 | indirect |
| Trenor Cameron C. III | Chief Medical Officer | 116,667 | 571,668 $ | Sep 15, 2026 | direct |
| Williams Sarah Joanne | Principal Accounting Officer | 66,311 | 324,924 $ | Sep 1, 2026 | direct |
| FitzPatrick Margaret M | Director | 10,708 | 52,469 $ | Sep 1, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Trenor Cameron C. III | Chief Medical Officer | Other | 116,667 | 0.00 | – |
| Sep 9, 2026 | Readnour Robin Shane | Director | Sell | 585 | 6.02 | 3,524 |
| Sep 9, 2026 | Readnour Robin Shane | Director | Sell | 523 | 6.02 | 3,151 |
| Sep 8, 2026 | Readnour Robin Shane | Director | Sell | 5,294 | 6.02 | 31,861 |
| Sep 8, 2026 | Readnour Robin Shane | Director | Sell | 4,725 | 6.02 | 28,436 |
| Sep 3, 2026 | Readnour Robin Shane | Director | Sell | 3,223 | 6.07 | 19,563 |
| Sep 3, 2026 | Readnour Robin Shane | Director | Sell | 2,877 | 6.07 | 17,463 |
| Sep 1, 2026 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 272 | 5.53 | 1,504 |
| Sep 1, 2026 | FitzPatrick Margaret M | Director | Buy | 2,098 | 5.53 | 11,602 |
| Aug 17, 2026 | Readnour Robin Shane | Director | Sell | 18,706 | 6.01 | 112,389 |
| Aug 17, 2026 | Readnour Robin Shane | Director | Sell | 16,696 | 6.01 | 100,313 |
| Aug 14, 2026 | Zakrzewski Joseph S | Director | Other | 405,880 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.